Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 88

1.

Pan-Cancer Analysis of Mitochondria Chaperone-Client Co-Expression Reveals Chaperone Functional Partitioning.

Galai G, Ben-David H, Levin L, Orth MF, Grünewald TGP, Pilosof S, Berstein S, Rotblat B.

Cancers (Basel). 2020 Mar 30;12(4). pii: E825. doi: 10.3390/cancers12040825.

2.

A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.

Orth MF, Buecklein VL, Kampmann E, Subklewe M, Noessner E, Cidre-Aranaz F, Romero-Pérez L, Wehweck FS, Lindner L, Issels R, Kirchner T, Altendorf-Hofmann A, Grünewald TGP, Knösel T.

Cancer Immunol Immunother. 2020 Mar 28. doi: 10.1007/s00262-020-02552-5. [Epub ahead of print]

PMID:
32222780
3.

High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma.

Orth MF, Hölting TLB, Dallmayer M, Wehweck FS, Paul T, Musa J, Baldauf MC, Surdez D, Delattre O, Knott MML, Romero-Pérez L, Kasan M, Cidre-Aranaz F, Gerke JS, Ohmura S, Li J, Marchetto A, Henssen AG, Özen Ö, Sugita S, Hasegawa T, Kanaseki T, Bertram S, Dirksen U, Hartmann W, Kirchner T, Grünewald TGP.

Cancers (Basel). 2020 Mar 10;12(3). pii: E644. doi: 10.3390/cancers12030644.

4.

Transcriptional Programs Define Intratumoral Heterogeneity of Ewing Sarcoma at Single-Cell Resolution.

Aynaud MM, Mirabeau O, Gruel N, Grossetête S, Boeva V, Durand S, Surdez D, Saulnier O, Zaïdi S, Gribkova S, Fouché A, Kairov U, Raynal V, Tirode F, Grünewald TGP, Bohec M, Baulande S, Janoueix-Lerosey I, Vert JP, Barillot E, Delattre O, Zinovyev A.

Cell Rep. 2020 Feb 11;30(6):1767-1779.e6. doi: 10.1016/j.celrep.2020.01.049.

5.

Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer.

Musa J, Grünewald TGP.

Mol Cell Oncol. 2019 Nov 6;7(1):1682924. doi: 10.1080/23723556.2019.1682924. eCollection 2020.

PMID:
31993496
6.

Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.

Knott MML, Hölting TLB, Ohmura S, Kirchner T, Cidre-Aranaz F, Grünewald TGP.

Cancer Metastasis Rev. 2019 Dec;38(4):625-642. doi: 10.1007/s10555-019-09839-9. Review.

7.

Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.

Rodríguez-Núñez P, Romero-Pérez L, Amaral AT, Puerto-Camacho P, Jordán C, Marcilla D, Grünewald TG, Alonso J, de Alava E, Díaz-Martín J.

J Pathol. 2020 Apr;250(4):374-386. doi: 10.1002/path.5379. Epub 2020 Feb 4.

PMID:
31880317
8.

Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.

Steinestel K, Trautmann M, Jansen EP, Dirksen U, Rehkämper J, Mikesch JH, Gerke JS, Orth MF, Sannino G, Arteaga MF, Rossig C, Wardelmann E, Grünewald TGP, Hartmann W.

Mol Oncol. 2020 Feb;14(2):248-260. doi: 10.1002/1878-0261.12610. Epub 2019 Dec 21.

9.

DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics.

Kommoss FKF, Stichel D, Schrimpf D, Kriegsmann M, Tessier-Cloutier B, Talhouk A, McAlpine JN, Chang KTE, Sturm D, Pfister SM, Romero-Pérez L, Kirchner T, Grünewald TGP, Buslei R, Sinn HP, Mechtersheimer G, Schirmacher P, Schmidt D, Lehr HA, Sahm F, Huntsman DG, Gilks CB, Kommoss F, von Deimling A, Koelsche C.

J Cancer Res Clin Oncol. 2020 Jan;146(1):97-104. doi: 10.1007/s00432-019-03093-w. Epub 2019 Nov 25.

PMID:
31768620
10.

Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.

Gerke JS, Orth MF, Tolkach Y, Romero-Pérez L, Wehweck FS, Stein S, Musa J, Knott MML, Hölting TLB, Li J, Sannino G, Marchetto A, Ohmura S, Cidre-Aranaz F, Müller-Nurasyid M, Strauch K, Stief C, Kristiansen G, Kirchner T, Buchner A, Grünewald TGP.

Int J Cancer. 2020 Apr 1;146(7):2036-2046. doi: 10.1002/ijc.32792. Epub 2019 Nov 29.

PMID:
31732966
11.

Clinical Evidence on the Interaction Between MLK4, KRAS and Microsatellite Instability to Determine the Prognosis of Early-Stage Colorectal Carcinoma.

Brandl L, Horst D, Grünewald TGP, Mayerle J, Sendelhofert A, Neumann J, Kirchner T, De Toni EN.

Cell Physiol Biochem. 2019;53(5):820-831. doi: 10.33594/000000175.

12.

Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes.

Musa J, Cidre-Aranaz F, Aynaud MM, Orth MF, Knott MML, Mirabeau O, Mazor G, Varon M, Hölting TLB, Grossetête S, Gartlgruber M, Surdez D, Gerke JS, Ohmura S, Marchetto A, Dallmayer M, Baldauf MC, Stein S, Sannino G, Li J, Romero-Pérez L, Westermann F, Hartmann W, Dirksen U, Gymrek M, Anderson ND, Shlien A, Rotblat B, Kirchner T, Delattre O, Grünewald TGP.

Nat Commun. 2019 Sep 11;10(1):4128. doi: 10.1038/s41467-019-12071-2.

13.

Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients.

Sannino G, Marchetto A, Ranft A, Jabar S, Zacherl C, Alba-Rubio R, Stein S, Wehweck FS, Kiran MM, Hölting TLB, Musa J, Romero-Pérez L, Cidre-Aranaz F, Knott MML, Li J, Jürgens H, Sastre A, Alonso J, Da Silveira W, Hardiman G, Gerke JS, Orth MF, Hartmann W, Kirchner T, Ohmura S, Dirksen U, Grünewald TGP.

EBioMedicine. 2019 Sep;47:156-162. doi: 10.1016/j.ebiom.2019.08.002. Epub 2019 Aug 16.

14.

STAG Mutations in Cancer.

Romero-Pérez L, Surdez D, Brunet E, Delattre O, Grünewald TGP.

Trends Cancer. 2019 Aug;5(8):506-520. doi: 10.1016/j.trecan.2019.07.001. Epub 2019 Jul 31. Review.

PMID:
31421907
15.

Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours.

Jones DTW, Banito A, Grünewald TGP, Haber M, Jäger N, Kool M, Milde T, Molenaar JJ, Nabbi A, Pugh TJ, Schleiermacher G, Smith MA, Westermann F, Pfister SM.

Nat Rev Cancer. 2019 Aug;19(8):420-438. doi: 10.1038/s41568-019-0169-x. Epub 2019 Jul 12. Review.

PMID:
31300807
16.

DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma.

Koelsche C, Kriegsmann M, Kommoss FKF, Stichel D, Kriegsmann K, Vokuhl C, Grünewald TGP, Romero-Pérez L, Kirchner T, de Alava E, Diaz-Martin J, Hartmann W, Baumhoer D, Antonescu CR, Szuhai K, Flucke U, Dirksen U, Pfister SM, Jones DTW, Mechtersheimer G, von Deimling A.

J Cancer Res Clin Oncol. 2019 May;145(5):1273-1281. doi: 10.1007/s00432-019-02895-2. Epub 2019 Mar 20.

PMID:
30895378
17.

Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma.

Dallmayer M, Li J, Ohmura S, Alba Rubio R, Baldauf MC, Hölting TLB, Musa J, Knott MML, Stein S, Cidre-Aranaz F, Wehweck FS, Romero-Pérez L, Gerke JS, Orth MF, Marchetto A, Kirchner T, Bach H, Sannino G, Grünewald TGP.

Cell Death Dis. 2019 Feb 11;10(2):116. doi: 10.1038/s41419-019-1372-0.

18.

Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity.

Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, Talebi A, Dehairs J, Escalona-Noguero C, Schmieder R, Cornfield T, Charlton C, Romero-Pérez L, Rossi M, Rinaldi G, Orth MF, Boon R, Kerstens A, Kwan SY, Faubert B, Méndez-Lucas A, Kopitz CC, Chen T, Fernandez-Garcia J, Duarte JAG, Schmitz AA, Steigemann P, Najimi M, Hägebarth A, Van Ginderachter JA, Sokal E, Gotoh N, Wong KK, Verfaillie C, Derua R, Munck S, Yuneva M, Beretta L, DeBerardinis RJ, Swinnen JV, Hodson L, Cassiman D, Verslype C, Christian S, Grünewald S, Grünewald TGP, Fendt SM.

Nature. 2019 Feb;566(7744):403-406. doi: 10.1038/s41586-019-0904-1. Epub 2019 Feb 6.

19.

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.

Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A.

Eur J Cancer. 2019 Mar;109:137-153. doi: 10.1016/j.ejca.2018.12.024. Epub 2019 Feb 2.

PMID:
30721788
20.

Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma.

Orth MF, Gerke JS, Knösel T, Altendorf-Hofmann A, Musa J, Alba-Rubio R, Stein S, Hölting TLB, Cidre-Aranaz F, Romero-Pérez L, Dallmayer M, Baldauf MC, Marchetto A, Sannino G, Knott MML, Wehweck F, Ohmura S, Li J, Hakozaki M, Kirchner T, Dandekar T, Butt E, Grünewald TGP.

Int J Cancer. 2019 Feb 15;144(4):859-867. doi: 10.1002/ijc.31903. Epub 2018 Dec 4.

Supplemental Content

Loading ...
Support Center